Efficacy of Mosquito Shield, a transfluthrin spatial emanator against wild, free-flying pyrethroid-resistant Anopheles gambiae s.l.; an experimental hut evaluation in Benin, West Africa

This experimental hut trial in Benin demonstrated that the transfluthrin-based spatial emanator Mosquito Shield™ significantly reduces landing, blood-feeding, and survival of pyrethroid-resistant *Anopheles gambiae* s.l. and *Mansonia africana*, supporting its potential as a complementary malaria control tool for WHO prequalification.

The Gist

The Big Picture: A New Shield Against Super-Mosquitoes

Imagine malaria mosquitoes as super-villains. For years, we've fought them with "insecticide-treated nets" (ITNs)—basically, mosquito nets that are coated in bug-killing poison. But these villains have evolved. In many parts of Africa, they have developed "superpowers" (resistance) that make the old poison useless. They can bite through the net or ignore the poison entirely.

The scientists in this study wanted to test a new weapon: Mosquito Shield™. Think of this not as a net, but as a scent-based force field. It's a small plastic pouch that hangs on your wall and slowly releases a smell (transfluthrin) that mosquitoes hate. It doesn't need electricity or a flame; it just works by filling the room with a "Keep Out" signal.

The goal? To see if this new "scent shield" can stop these super-villains from getting into your house and biting you, even when they are resistant to the old poisons.

---

The Experiment: The "Mosquito Hotel"

To test this, the researchers built 16 special "experimental huts" in Benin, West Africa. These aren't normal houses; they are like mosquito hotels designed specifically for testing.

• The Setup: They built 8 huts with the new Mosquito Shield™ hanging on the walls and 8 huts with a fake, empty pouch (the placebo).
• The Guests: They invited real, wild mosquitoes (specifically the Anopheles gambiae, the main malaria carrier, and Mansonia africana, a nuisance mosquito that spreads other diseases) to visit.
• The Volunteers: Brave human volunteers slept in these huts. In some huts, they were just sitting there (to see how many mosquitoes landed on them). In others, they slept under a net with tiny holes (to see if the mosquitoes could still get in and bite).

What Happened? (The Results)

The results were like a winning game for the Mosquito Shield™, even against the "super-villain" mosquitoes.

1. The "Do Not Disturb" Sign Worked (Deterrence)
Mosquitoes are like nosy neighbors who love to peek into your house. The study found that the scent from the Mosquito Shield™ acted like a giant "Do Not Disturb" sign.

• The Result: About 48% fewer mosquitoes even tried to enter the huts with the shield. They smelled the air, decided it was too unpleasant, and flew away.

2. The "No Bite" Zone (Protection)
For the mosquitoes that did manage to get inside, the shield acted like an invisible bubble.

• The Result: Even though the mosquitoes were inside, they couldn't find the humans to bite. The study showed a 64% reduction in successful blood meals. It's as if the humans were wearing an invisible cloak that made them invisible to the mosquitoes' hunger sensors.

3. The "Poison Trap" (Mortality)
Here is the surprising part. Usually, these "scent shields" just push mosquitoes away; they don't kill them. But in this study, the shield acted like a slow-acting trap.

• The Result: Nearly 50% of the malaria mosquitoes that entered the shielded huts died within 24 hours. Even though these mosquitoes were "super-resistant" to the old poisons, this specific scent (transfluthrin) was still strong enough to kill them. It's like a villain who is immune to bullets but gets knocked out by a specific smell.

4. The Bonus Effect: Stopping the Nuisance
The shield didn't just work on malaria mosquitoes; it also worked on Mansonia africana, a mosquito that causes itching and spreads lymphatic filariasis (a disease that causes swelling).

• The Result: It was almost a total wipeout for this species, killing over 96% of them. It's like having a security system that stops both burglars and raccoons from entering your house.

The Catch: It's Not Magic Forever

The study ran for 32 days (about a month).

• Days 1–19: The shield was at its peak, working like a brand-new air freshener that fills the whole room perfectly.
• Days 25–32: The scent started to fade, like an old candle that has burned down. The protection dropped a bit, but it was still better than doing nothing.

The Bottom Line

This study is a green light for a new tool in the fight against malaria.

• Why it matters: In West Africa, where mosquitoes have become "super-resistant" to old nets, we need new tricks. Mosquito Shield™ is a simple, passive tool (no batteries, no fire) that can be hung on a wall.
• The Strategy: It's not meant to replace your bed net. Think of it as layering your armor. You wear the net at night, and you hang the shield on the wall. Together, they create a fortress that the mosquitoes can't easily break into.

In short: This paper proves that a simple, hanging pouch can significantly reduce mosquito bites and even kill resistant mosquitoes in West Africa, offering a powerful new way to protect families from malaria.

Technical Summary

1. Problem Statement

• Stalled Malaria Progress: Global malaria reduction has stalled due to insecticide resistance in vectors, declining durability of insecticide-treated nets (ITNs), and reduced coverage of indoor residual spraying (IRS).
• Resistance Crisis: The primary vector, Anopheles gambiae s.l., in West Africa exhibits high-intensity resistance to pyrethroids (the main class of insecticides used in ITNs), rendering standard interventions less effective.
• Need for Complementary Tools: There is an urgent need for new, complementary vector control tools that can function effectively in areas of high resistance and close protection gaps left by ITNs (e.g., when people are not sleeping under nets).
• Evidence Gap: While spatial emanators (passive repellents) have shown efficacy in East Africa and against Aedes mosquitoes, robust entomological evidence for their efficacy against pyrethroid-resistant Anopheles in West Africa was lacking, hindering WHO prequalification and procurement.

2. Methodology

• Study Design: A Good Laboratory Practice (GLP)-compliant experimental hut trial conducted at the Covè field station in southern Benin.
• Location & Vector: The study took place in an area with intense pyrethroid resistance. The target vector was wild, free-flying Anopheles gambiae s.l. (predominantly An. coluzzii). A nuisance vector, Mansonia africana, was also monitored.
• Intervention: Mosquito Shield™, a passive spatial emanator containing 110 mg of transfluthrin. Four devices were hung on interior walls of experimental huts at ~2/3 height.
• Control: Placebo-treated huts (identical setup without active ingredient).
• Duration: Two consecutive 32-day product life cycles (July–August 2024 and November–December 2024), covering different transmission seasons.
• Data Collection Methods:
  • Human Landing Catches (HLC): Trained volunteers collected mosquitoes landing on their legs to measure protective efficacy against landing.
  • Mosquito Aspiration: Volunteers slept under untreated nets with holes; mosquitoes were aspirated from under the net, the room, and the veranda to measure deterrence, blood-feeding inhibition, and personal protection.
• Endpoints:
  • Primary: Protective efficacy against landing (HLC) and personal protection against blood-feeding (Aspiration).
  • Secondary: Deterrence, exophily (tendency to exit), mortality, and blood-feeding inhibition.
• Susceptibility Testing: WHO tube and bottle bioassays were conducted on local F1 progeny to confirm resistance profiles to transfluthrin and other insecticides.
• Statistical Analysis: Negative binomial regression for count data and logistic regression for proportional data, adjusting for hut, round, day, and sleeper variability.

3. Key Contributions

• First GLP-compliant West African Data: Provides the first rigorous, GLP-compliant experimental hut data on Mosquito Shield™ efficacy in West Africa, a region with distinct resistance mechanisms compared to East Africa.
• Validation in High-Resistance Settings: Demonstrates that passive spatial emanators remain effective even against An. gambiae s.l. populations with confirmed high-level resistance to pyrethroids and transfluthrin.
• Dual-Method Validation: Simultaneously validates the product using both HLC (gold standard for landing) and aspiration methods (standard for WHO hut trials), showing consistency across methodologies.
• Broader Vector Impact: Documents significant efficacy against Mansonia africana, a vector of lymphatic filariasis and a major nuisance mosquito, suggesting potential for integrated vector management.
• Support for WHO Prequalification: Generates the critical efficacy data required for the World Health Organization to prequalify the product for UN procurement.

4. Key Results

• Susceptibility Profile: Local mosquitoes showed <55% mortality to standard pyrethroids and <15% to DDT. While transfluthrin caused 100% knockdown, mortality was only 32%, confirming high resistance.
• Protective Efficacy (HLC):
  • An. gambiae s.l.: Mosquito Shield™ reduced landing by 43.0% (Model-adjusted; 95% CI: 24.0–57.0; p < 0.001).
  • Mansonia africana: Reduced landing by 38.0% (95% CI: 12.0–57.0; p = 0.008).
• Personal Protection & Blood-Feeding (Aspiration):
  • Deterrence: 48.5% reduction in hut entry.
  • Blood-feeding Inhibition: 29.9% reduction in blood-fed mosquitoes.
  • Personal Protection: 64.0% (95% CI: 21.9–81.8; p < 0.001) reduction in blood-feeding risk.
• Mortality (Insecticidal Effect):
  • Despite resistance, Mosquito Shield™ induced significant mortality: 49.0% for An. gambiae s.l. (HLC) and 22.7% (Aspiration).
  • Mansonia africana mortality was exceptionally high at 96.8%.
• Temporal Dynamics: Efficacy peaked between days 13–19 of the 32-day cycle. Efficacy against An. gambiae remained stable, while efficacy against Mansonia declined toward the end of the cycle.
• Behavioral Effects: The product significantly reduced hourly biting rates, particularly during peak evening (19:00–21:00) and early morning (03:00–05:00) hours when people are often outside or not under nets.

5. Significance

• Public Health Impact: The study confirms that Mosquito Shield™ can significantly reduce human-vector contact and blood-feeding even in the presence of intense pyrethroid resistance. This supports its use as a complementary tool to ITNs to close protection gaps.
• Policy Implications: The results directly support the WHO prequalification of Mosquito Shield™, enabling its procurement by UN agencies and national malaria programs.
• Integrated Vector Management: The high efficacy against Mansonia africana suggests the product could be a dual-purpose tool for controlling both malaria and lymphatic filariasis, as well as nuisance biting.
• Strategic Deployment: The data highlights the importance of replacing devices before the 32-day cycle ends to maintain peak efficacy, informing operational guidelines for mass distribution.
• Future Directions: The study underscores the need for longer-lasting spatial emanators (e.g., 12-month duration) to reduce replacement frequency and improve cost-effectiveness in long transmission seasons.